Strategies to limit the severe pandemic and to manage coronavirus disease (COVID-19) patients strongly depend on readily available, accurate and reliable RT-PCR assays to detect the genome of the causative agent acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in biosamples. The first full-length SARS-CoV-2 genome sequence was made publicly available in early January 2020 \[[@r1]\] and, soon after, various RT-PCR assays were reported by academic laboratories, public health agencies and diagnostics companies \[[@r2]-[@r6]\]. Their overall performance and relative sensitivity are largely unclear.

The aim of this study was to compare the inter-laboratory and inter-method sensitivity of different RT-PCR assays by providing a blinded, frozen dilution series of a nucleic acid extract of a highly positive biosample to seven different diagnostic laboratories in Germany in March 2020.

Sample preparation and study design
===================================

Nucleic acids were pooled from multiple extractions of one SARS-CoV-2-positive stool sample using the QIAsymphony DSP Virus/Pathogen Kit (Qiagen, Hilden, Germany). This stool sample was from a 5-year-old child with COVID-19 \[[@r7]\] and was chosen because of high initial PCR signals and sufficient sample availability to generate large quantities of eluate for further distribution. Of note, no PCR inhibition was observed for detection of the spiked-in extraction RNA control (QuantiNova IC Probe Assays Red 650, Qiagen). A 1:10 dilution series was prepared and aliquots were labelled in a blinded fashion to be shipped on dry ice to participating laboratories in March 2020. Participants were instructed to perform the diagnostic assays used at their centre for SARS-CoV-2 detection in quadruplicate using 5 µL of the aliquot per reaction. All results were reported back to the initiating laboratory (Laboratory 1) before the results were unblinded. The details of all these PCR-based assays are summarised in the [Table](#t1){ref-type="table"}.

###### Specifications of different molecular assays used for detection of SARS-CoV-2, Germany, March 2020 (n =11 test systems with 34 different reaction--lab combinations)

  Laboratory                                                     Protocol                               Target                                       Primer/probe                                     Supermix                                                              Instrument
  -------------------------------------------------------------- -------------------------------------- -------------------------------------------- ------------------------------------------------ --------------------------------------------------------------------- ----------------------------------
  Laboratory 1                                                   CDC \[[@r2]\]                          N1, N2, N3                                   Ella Biotech                                     QuantiNova Multiplex RT-PCR Kit                                       Roche LightCycler 480 II
  Charité \[[@r3],[@r4]\]                                        E, N, RdRp                             Tib-Molbiol                                  QuantiNova Multiplex RT-PCR Kit                  Roche LightCycler 480 II                                              
  Modified Charité RdRp primers                                  RdRp                                   Ella Biotech                                 QuantiNova Multiplex RT-PCR Kit                  Roche LightCycler 480 II                                              
  Applied Biosystems TaqMan 2019-nCoV Assay Kit v1               S, N, RdRp                             Commercial kit                               TaqMan Fast Virus 1-Step Master Mix              Applied Biosystems 7500 fast                                          
  Seegene Allplex 2019-nCoV Assay                                E, N, RdRp                             Commercial kit                               Commercial kit                                   Biorad CFX 96 Real-Time System                                        
  Digital droplet PCR using CDC primer and probe sequences       N1, N2, N3                             Ella primers/IDT ZEN Double-Quenched Probe   BioRad 1-Step RT-ddPCR Advanced Kit for Probes   Biorad QX200 droplet digital PCR                                      
  Digital droplet PCR using Charité primer and probe sequences   E, N, RdRp                             Ella primers/IDT ZEN Double-Quenched Probe   BioRad 1-Step RT-ddPCR Advanced Kit for Probes   Biorad QX200 droplet digital PCR                                      
  Laboratory 2                                                   Charité \[3,[@r4]\]                    E, RdRp                                      Tib-Molbiol                                      Superscript III One-Step RT-PCR System With Platinum Taq Polymerase   Roche LightCcycler 480 II
  Laboratory 3                                                   Charité \[[@r3],[@r4]\]                E, RdRp (2 or 1 and 2)                       Tib-Molbiol                                      Superscript III One-Step RT-PCR System With Platinum Taq Polymerase   Biorad CFX 96 Real-Time System
  Altona diagnostics RealSstar SARS-CoV-2 RT-PCR                 Beta-CoV, SARS-CoV-2                   Commercial kit                               Commercial kit                                   Biorad CFX 96 Real-Time System                                        
  Laboratory 4                                                   Charité \[[@r3],[@r4]\]                E, RdRp                                      Tib-Molbiol                                      RNA to CT 1-step                                                      Applied Biosystems 7500 fast
  Laboratory developed test                                      M, S                                   Tib-Molbiol                                  Roche Multiplex RNA Virusmaster                  Roche LightCycler 480 II                                              
  Laboratory 5                                                   Charité \[[@r3],[@r4]\]                E, N, RdRp                                   Tib-Molbiol                                      Quantitect Virus +ROX Vial Kit                                        Applied Biosystems 7500 fast
  CDC \[[@r2]\]                                                  N1, N2, N3                             Microsynth                                   Quantitect Virus +ROX Vial Kit                   Applied Biosystems 7500 fast                                          
  Laboratory 6                                                   Charité \[[@r3],[@r4]\]                E, N, RdRp                                   Tib-Molbiol                                      Qiagen one step RT-PCR Kit                                            Bio Molecular Systems MIC Cycler
  Laboratory 7                                                   Mikrogen ampliCube Coronavirus Panel   Various coronaviruses                        Commercial kit                                   Commercial kit                                                        Roche LightCycler 480 II
  Mikrogen ampliCube Coronavirus SARS-CoV-2                      E, Orf1a                               Commercial kit                               Commercial kit                                   Roche LightCycler 480 II                                              

Beta-CoV: Betacoronavirus; CDC: Centers for Disease Control and Prevention; E: envelope gene; N: nucleocapsid gene; Orf: open reading frame; RdRp: RNA-dependent RNA-polymerase gene; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; WHO: World Health Organization.

Performing laboratory, assay protocol, target, manufacturer of primer/probe, PCR chemistry and instrument are indicated.

In parallel, samples were quantified using the One-Step RT-digital droplet (dd)PCR Advanced Kit for Probes (BioRad, Feldkirchen, Germany) on the BioRad QX200 platform. Primer and probe sequences were used for detection of the SARS-CoV-2 *nucleocapsid* gene (*N*) as published by the Centers for Disease Control and Prevention (CDC) \[[@r2]\] and the ﻿*envelope* gene (*E*), the ﻿*RNA-dependent RNA polymerase* (*RdRp*) gene and the *N* gene as published by Corman et al. (referred to as Charité protocol) \[[@r3]\] ([Figure 1](#f1){ref-type="fig"}).

![Digital droplet PCR quantification of the distributed dilution series of nucleic acid eluate of SARS-CoV-2-positive clinical material, Germany, March 2020](2001057-f1){#f1}

The undiluted sample showed between 4,325 and 5,015 SARS-CoV-2 RNA copies per reaction using 5 µL of eluate for the CDC *N1*, *N2*, *N3* and Charité *E*protocols, but only 850 and 1,951 RNA copies for the Charité *N* and *P* primer/probe combinations ([Figure 1A](#f1){ref-type="fig"}), respectively, indicating a lower sensitivity of the latter. The 1:10 dilution series displayed good linearity down to a calculated concentration of 0.4 RNA copies per reaction at the 10^−4^ dilution for both the CDC *N1* and *N2* primer/probe combinations ([Figure 1B](#f1){ref-type="fig"}).

Multicentre and multi-assay comparison
======================================

Result interpretations from the seven participating laboratories are summarised in [Figure 2](#f2){ref-type="fig"} displaying the number of replicates scored positive by the respective laboratory for each method and dilution. Most methods reliably detected the sample at the 10^−3^ dilution, which is equivalent to ca 5 RNA copies for the CDC *N1*, *N2*, *N3* and Charité *E* reactions based on the absolute quantification by ddPCR. Of note, the Seegene Allplex 2019-nCoV Assay gave negative results for all four replicates in the *E* gene at the 10^−3^ dilution, while reporting positive results for *N* and *RdRp* (Laboratory 1). According to the manufacturer's instructions at the time of analysis, this would have been interpreted as an inconclusive result. Of note, the *RdRp* primer/probe did not show any positive result at the 10^−4^ dilution.

![Dilution series comparing various RT-PCR assays for the detection of SARS-CoV-2 at different laboratories, Germany, March 2020 (n =11 test systems with 34 reaction--lab combinations)](2001057-f2){#f2}

Sequence analysis of primer pairs
=================================

Driven by false-negative results for samples with low PCR-positivity using the original Charité *RdRp* reaction (see below and others \[[@r8],[@r9]\]), we compared the primer/probe sequences with currently available SARS-CoV-2 genomes. When compared with all genomes available on GISAID (9,184 SARS-CoV-2 genomes on 15 April 2020, [Supplement](/content/10.2807/1560-7917.ES.2020.25.24.2001057#supplementary_data)), the regions used for amplification in the CDC and Charité protocol are highly conserved: Only 1.55%, 0.45% and 2.4% of genome sequences contain any kind of mismatch within the primer/probe regions of the CDC *N1*, *N2* and *N3* protocols, respectively, and 0.25%, 0.29% and 0.67% in the primer/probe regions of the Charité *E*, *RdRp* and *N* protocols, respectively.

The Charité *RdRp* reverse primer contains an ambiguity base at position 15,519 that does not match the reference sequence (Wuhan-Hu-1/2019), with an S (i.e. G or C) instead of T for the reverse complement ([Supplementary Figure S1](/content/10.2807/1560-7917.ES.2020.25.24.2001057#supplementary_data)). The other ambiguity base at 15,528 showing Y (i.e. C or T) should be changed to T because the currently circulating viruses have a T at this position and no polymorphisms were detected in any of the 9,184 sequences submitted to date (accession date: 15 April 2020). Based on computation using Primer Express v3.0 (Applied Biosystems, Dreieich, Germany) annealing temperatures were predicted to be 64 °C for the *RdRp* forward and 51 °C for the *RdRp* reverse primer of the Charité protocol. This temperature difference may result in reduced PCR efficiency. To address this issue, modified *RdRp* primers were synthesised as shown in [Supplementary Figure S1](/content/10.2807/1560-7917.ES.2020.25.24.2001057#supplementary_data) and tested in comparison with the original primers.

Differential detection of respiratory samples with low PCR positivity
=====================================================================

Testing the dilution series with these modified *RdRp* primers (see above and [Supplementary Figure S1](/content/10.2807/1560-7917.ES.2020.25.24.2001057#supplementary_data)) yielded positive results for two additional dilution steps (10^-3^ and 10^-4^) compared with the original Charité *RdRp* primers ([Figure 1](#f1){ref-type="fig"}). To further compare the sensitivity of these modified *RdRp* primers with the original version of the Charité *RdRp* primers and the Charité *E* and the CDC *N1* reaction, we retested 28 eluates of clinical respiratory specimens from the diagnostic unit at Laboratory 1 that had shown crossing point (Cp) values \> 35 in the initial CDC *N1* reaction. Using the original version of the confirmatory Charité *RdRp* primers, 16 of 28 samples tested negative, but 11 of these showed positive results using the modified primers ([Figure 3](#f3){ref-type="fig"}). Overall, the detection by the Charité *E*, modified Charité *RdRp*, and CDC *N1* reactions were robust. Notably, six and seven of these 28 respiratory samples scored negative or at the limit of detection (Cp = 40) in the Charité *E* and modified Charité *RdRp* reactions, while only one sample came up negative in retesting in the CDC *N1* reaction (p = 0.04 and p = 0.02, chi-squared-test comparing Charité *E* and modified *RdRp* to CDC *N1*, respectively). Of note, in a routine clinical setting, the CDC *N1* reaction also detected SARS-CoV-2 RNA in nucleic acid extracts from 37 of 83 sera (45%) from COVID-19 patients in intensive care units, with a positive correlation of their Cp values with those of the corresponding respiratory material (Spearman Rank correlation co-efficient r=0.4285, p (two-tailed) \< 0.0001 (data not shown)).

![RT-PCR results of respiratory samples with low positivity, SARS-CoV-2 detection, Germany, March 2020 (n = 28 samples)](2001057-f3){#f3}

Conclusion
==========

The majority of RT-PCR assays for SARS-CoV-2 examined in this study detected ca 5 RNA copies per reaction, reflecting a high sensitivity and their suitability for screening purposes world-wide. A reduced sensitivity was noted for the original Charité *RdRp* gene confirmatory protocol, which may have impacted the confirmation of some COVID-19 cases in the early weeks of the pandemic. The protocol needs to be amended to improve the sensitivity of the *RdRp* reaction. The CDC *N1* primer/probe set was sensitive and robust for detection of SARS-CoV-2 in nucleic acid extracts from respiratory material, stool and serum from COVID-19 patients.
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